Search results for: 'next or maritime or vessel'
- Did you mean
- ne02 or maritime or vessel
- ne00 or maritime or vessel
- Related search terms
- Next-Generation 911—The Future of Public Safety, Forecast to 2023
- Next Generation E911 (NG911) Market Insight
- Next Generation 911: The Future of Public Safety—Forecast to 2026
- Next Generation 911: The Future of Public Safety-Forecast to 2027
- vessel fleet management
-
30 Apr 2019  |  Global  |  Technology Research
Technological Advances Enabling Stem Cells Reprogramming
Technologies Paving New Avenues to Drive Breakthrough Research Toward the Discovery of Next Generation Therapeutics
Since the advent of stem cells reprogramming after the discovery of the differentiation factors that allow the creation of human induced pluripotent stem cells, researchers all around the world are strongly committed to develop novel methods to design and build human stem cells. Indeed, there is an increasing demand for the more efficient product...
$4,950.00
Special Price $3,712.50 save 25 %
-
20 Dec 2022  |  Global  |  Technology Research
Advances and Growth Opportunities in RNA Vaccines
Technology Innovations and Investments Bolster Next-generation Prophylactic and Therapeutic RNA Vaccines
RNA therapeutics and vaccines have been around for a long time, but the COVID-19 pandemic enabled their mass-market commercialization. Industry players saw mRNA vaccines developed for COVID-19 as effective for reducing the impact of the SARS-CoV-2 virus in populations. Moderna emerged as the first player to develop and commercialize an mRNA vaccine...
$4,950.00
Special Price $3,712.50 save 25 %
-
10 May 2023  |  Global  |  Market Research
Growth Opportunities in the Biologics Contract Development and Manufacturing Organization Sector
Value Chain Expansion to Support Next generation Biologics Drives Future Growth Potential
This research service provides an overview of the global biologics contract development and manufacturing organization (bio-CDMO) market and a 6-year market revenue forecast (2023 to 2028). The geographic scope covers three key regions, namely North America (NA); Europe; and Asia-Pacific (APAC). The report offers a detailed segment analysis of...
$4,950.00
Special Price $3,712.50 save 25 %
-
24 Aug 2021  |  North America  |  Market Research
US and EU Biotech Industry VC Investment Growth Opportunities
Future Growth Potential Driven by Next-generation Cell and Gene Platform Technology Powered by AI
With this research service, Frost & Sullivan provides critical insights into the biotech, and cell and gene therapy (CGT) venture capital (VC) investment trends highlighting the growth opportunities, key countries in the VC environment, and major trends in cell and gene therapy segment. The study also identifies actionable growth opportunities for ...
$2,450.00
Special Price $1,837.50 save 25 %
-
22 Nov 2021  |  Global  |  Technology Research
Technological Advances in RNA Stabilization & Delivery
LNP- and Bioconjugation-based Nonviral RNA Delivery Technologies to Gain Momentum in the Next 3 Years
RNA therapeutics is a rapidly expanding field of next-generation medicine. RNA therapy typically comprises 4 different classes of molecules: non-codingRNA (ncRNA), antisense oligonucleotide (ASO), messengerRNA (mRNA), and RNA aptamer. Small ncRNAs are like a double-edged sword; they can either up- or down-regulate specific genes. Contrarily, long...
$4,950.00
Special Price $3,712.50 save 25 %
-
19 Aug 2022  |  North America  |  Market Research
Global Antibody Therapeutics Growth Opportunities
The Evolution of Next-generation Immuno-oncology Therapies for Multiple Tumor Antigens is Poised to Drive Market Growth
Market growth is likely to be fueled by the growing utilization of cost-effective and efficient continuous manufacturing processes and single-use bioreactors for production, which will also reduce the time between development and commercialization. Favorable regulatory reforms in emerging Asian countries are encouraging the manufacture and introduc...
$2,450.00
Special Price $1,837.50 save 25 %
-
25 Jun 2024  |  Global  |  Market Research
Growth Opportunities in Biologics Contract Development and Manufacturing Organizations, 2024 2029
Risk-sharing Business Models for Next-generation Biologics Will Drive Bio-CDMO Growth and Spur Future Potential
By 2023, biologics constituted 44% of the therapeutic pipeline, with antibodies and recombinant proteins as leading categories. Nevertheless, advancements in these fields decelerated, with most of the expansion happening in heterologous cell treatments, synthetic nucleic acids, and viruses. The global biologics pipeline will shift toward more compl...
$4,950.00
Special Price $3,712.50 save 25 %
-
31 Jan 2020  |  North America  |  Market Research
Predictions for the Global Life Sciences Industry, 2020
COVID-19 Pandemic will Drive New Digital-tech Adoption in Drug Discovery and Testing Services, and Federal Funding will Encourage Stronger Product Pipelines
The growth trajectory of the global life sciences industry has benefited from a combination of novel technologies such as CRISPR-Cas9, microbiome and single-cell, relaxation of entry barriers in markets like China, and better-defined regulatory frameworks around next-generation therapies and companion diagnostics. A common denominator of growth a...
$1,500.00
Special Price $1,125.00 save 25 %
-
15 Feb 2022  |  North America  |  Market Research
Global Biologics Contract Development and Manufacturing Organization Profiles and Growth Opportunities
The Contract Research, Development, and Manufacturing Organization Business Model to Drive Future Growth Potential
Frost & Sullivan provides comprehensive insights into the global biologics contract development and manufacturing organization (bio-CDMO) market, including emerging trends, growth opportunities, and profiles of leading bio-CDMOs and their business model evolution. The growth of next-generation biologics and personalized therapies and the emergence ...
$2,450.00
Special Price $1,837.50 save 25 %
-
14 Jun 2024  |  Global  |  Market Research
Growth Opportunities in Global Diabetes and Obesity Therapeutics, 2024 2028
GLP-1 RA Drug Class, Combination Therapies, and Digital Convergence for Affordable Disease Management Drive Growth
Globally, diagnosis of metabolic diseases such as type 2 diabetes and obesity have increased. Since the COVID-19 pandemic, the global prevalence of obesity has worsened. Obesity is considered a main precursor of diabetes and contributes an estimated 80% to 85% toward the risk of type 2 diabetes. As a result, the financial burden associated with hea...
$4,950.00
Special Price $3,712.50 save 25 %